Evidence map›Paper›PMID 28229281›Full record

ReviewPediatric nephrology (Berlin, Germany)2018

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Christian Morath, Anita Schmitt, Florian Kälble, Martin Zeier, Michael Schmitt, Flavius Sandra-Petrescu, Gerhard Opelz, Peter Terness, Matthias Schaier, Christian Kleist

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian MorathDivision of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany. christian.morath@med.uni-heidelberg.de.
Anita SchmittDepartment of Internal Medicine V, GMP Core Facility, University of Heidelberg, Heidelberg, Germany.
Florian KälbleDivision of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.
Martin ZeierDivision of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, GMP Core Facility, University of Heidelberg, Heidelberg, Germany.
Flavius Sandra-PetrescuDepartment of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
Gerhard OpelzDepartment of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
Peter TernessDepartment of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
Matthias SchaierDivision of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.
Christian KleistDepartment of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative immunosuppressive regimens that resolve this therapeutic dilemma. Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness have been tested in early phase I and phase II clinical trials in kidney transplantation. The aim of this overview is to summarize current cell therapeutic approaches to immunosuppression in clinical kidney transplantation with a focus on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). MICs show great promise as a therapeutic agent to achieve the rapid and durable establishment of donor-unresponsiveness in living-donor kidney transplantation. Cell-based therapeutic approaches may eventually revolutionize immunosuppression in kidney transplantation in the near future.

Indexed as

HumansImmunosuppression TherapyKidney TransplantationMitomycinMyeloid-Derived Suppressor CellsNucleic Acid Synthesis InhibitorsTransplantation ToleranceMitomycinNucleic Acid Synthesis InhibitorsImmunosuppressionMitomycin C-induced cellsMyeloid suppressor cellsRegulatory T cellsToleranceTransplantation

Identifiers

PMID28229281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.